ArticleSubstance abuse treatment, prevention, and policy2025
Differences between men who have sex with men that use drugs and engage in chemsex and those who do not engage in chemsex in the French ANRS-PREVENIR cohort: the need to rethink harm reduction services.
Article in Substance abuse treatment, prevention, and policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From chemsex to a broader drug-use for sex landscape: Comparing two cross-sectional surveys on men who have sex with men in Italy.International journal of STD & AIDS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn increasing number of studies are exploring the profiles of men who have sex with men (MSM) in the context of the sexualized use of drugs (chemsex). However, less attention has been paid to MSM who use drugs but do not engage in chemsex. We do not know to what extent the latter are different from the former, or whether they require similar harm reduction services. This study aimed to compare both populations in terms of their sexual risk practices, health, and pre-exposure prophylaxis (PrEP) use.
methodsWe used longitudinal data from the ongoing French cohort study ANRS-PREVENIR, which comprises 3076 MSM receiving PrEP. Analyses were conducted on MSM who engaged in chemsex, MSM who used drugs but did not engage in chemsex, and MSM who did not use drugs. Only persons with available data from at least one follow-up visit between M0 and M36 were included, representing 19,375 visits. We built a three-category outcome: (i) MSM who did not use drugs (non-DU), (ii) MSM who used drugs but did not engage in chemsex (DU), and (iii) MSM who engaged in chemsex (CX). A multinomial logistic functional form was used to estimate odds-ratios and 95% confidence intervals, using the DU category as a reference.
resultsAmong the 2493 cohort participants, at baseline, 62.8%, 22.5%, and 14.6% of the participants were classified in the non-DU, DU, and CX categories, respectively. Compared to DU, non-DU were less likely to (i) declare fisting/BDSM practices, (ii) have a moderately risky sex life, ii) report lifetime PrEP use. Compared to DU, CX also had lower alcohol consumption, and were less likely to have (i) a tertiary education qualification, and (ii) a main partner; in contrast, CX were more likely to be depressed. CX were more likely to report fisting/BDSM practices, but less likely not to use PrEP and to report suboptimal PrEP adherence compared to DU participants.
conclusionsDifferences between the DU and CX populations were observed; the latter were more likely to (i) have at-risk sexual practices, (ii) suffer from depression, and (iii) have optimal PrEP adherence. It is essential to provide suitable mental health services to people who engage in chemsex, and to implement tailored sexual health and harm reduction services to MSM who use drugs but who do not engage in chemsex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.